196 related articles for article (PubMed ID: 21839500)
1. Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia.
Tropé A; Jonassen CM; Sjøborg KD; Nygård M; Dahl FA; Alfsen GC; Lie AK
Gynecol Oncol; 2011 Nov; 123(2):257-62. PubMed ID: 21839500
[TBL] [Abstract][Full Text] [Related]
2. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
[TBL] [Abstract][Full Text] [Related]
3. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds.
Tropé A; Sjøborg KD; Nygård M; Røysland K; Campbell S; Alfsen GC; Jonassen CM
J Clin Microbiol; 2012 Jun; 50(6):1927-35. PubMed ID: 22518869
[TBL] [Abstract][Full Text] [Related]
4. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear.
Molden T; Nygård JF; Kraus I; Karlsen F; Nygård M; Skare GB; Skomedal H; Thoresen SO; Hagmar B
Int J Cancer; 2005 May; 114(6):973-6. PubMed ID: 15645423
[TBL] [Abstract][Full Text] [Related]
5. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion.
Molden T; Kraus I; Karlsen F; Skomedal H; Nygård JF; Hagmar B
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):367-72. PubMed ID: 15734959
[TBL] [Abstract][Full Text] [Related]
6. Prediction of residual/recurrent disease by HPV genotype after loop excision procedure for high-grade cervical intraepithelial neoplasia with negative margins.
Wu D; Zheng Y; Chen W; Guo C; Yu J; Chen G; Huang Y
Aust N Z J Obstet Gynaecol; 2011 Apr; 51(2):114-8. PubMed ID: 21466511
[TBL] [Abstract][Full Text] [Related]
7. Separate analysis of human papillomavirus E6 and E7 messenger RNAs to predict cervical neoplasia progression.
Liu S; Minaguchi T; Lachkar B; Zhang S; Xu C; Tenjimbayashi Y; Shikama A; Tasaka N; Akiyama A; Sakurai M; Nakao S; Ochi H; Onuki M; Matsumoto K; Yoshikawa H; Satoh T
PLoS One; 2018; 13(2):e0193061. PubMed ID: 29466435
[TBL] [Abstract][Full Text] [Related]
8. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia.
Tropé A; Sjøborg K; Eskild A; Cuschieri K; Eriksen T; Thoresen S; Steinbakk M; Laurak V; Jonassen CM; Westerhagen U; Jacobsen MB; Lie AK
J Clin Microbiol; 2009 Aug; 47(8):2458-64. PubMed ID: 19535524
[TBL] [Abstract][Full Text] [Related]
9. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.
Rijkaart DC; Heideman DA; Coupe VM; Brink AA; Verheijen RH; Skomedal H; Karlsen F; Morland E; Snijders PJ; Meijer CJ
J Clin Microbiol; 2012 Jul; 50(7):2390-6. PubMed ID: 22553244
[TBL] [Abstract][Full Text] [Related]
10. High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia.
Persson M; Brismar Wendel S; Ljungblad L; Johansson B; Weiderpass E; Andersson S
Oncol Rep; 2012 Jul; 28(1):346-52. PubMed ID: 22484610
[TBL] [Abstract][Full Text] [Related]
11. Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women.
Luttmer R; Berkhof J; Dijkstra MG; van Kemenade FJ; Snijders PJ; Heideman DA; Meijer CJ
J Clin Virol; 2015 Jun; 67():59-66. PubMed ID: 25959161
[TBL] [Abstract][Full Text] [Related]
12. HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy.
Sørbye SW; Arbyn M; Fismen S; Gutteberg TJ; Mortensen ES
PLoS One; 2011; 6(10):e26022. PubMed ID: 21998748
[TBL] [Abstract][Full Text] [Related]
13. Human papilloma virus testing in patient follow-up post cone biopsy due to high-grade cervical intraepithelial neoplasia.
Almog B; Gamzu R; Kuperminc MJ; Levin I; Fainaru O; Niv J; Bar-Am A
Gynecol Oncol; 2003 Mar; 88(3):345-50. PubMed ID: 12648585
[TBL] [Abstract][Full Text] [Related]
14. Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3.
Ovestad IT; Vennestrøm U; Andersen L; Gudlaugsson E; Munk AC; Malpica A; Feng W; Voorhorst F; Janssen EA; Baak JP
Gynecol Oncol; 2011 Nov; 123(2):278-83. PubMed ID: 21835440
[TBL] [Abstract][Full Text] [Related]
15. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
16. Triage of low-grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests-A prospective population-based register study.
Reinholdt K; Juul KE; Dehlendorff C; Munk C; Kjaer SK; Thomsen LT
Acta Obstet Gynecol Scand; 2020 Feb; 99(2):204-212. PubMed ID: 31562779
[TBL] [Abstract][Full Text] [Related]
17. Follow-up by combined cytology and human papillomavirus testing for patients post-cone biopsy: results of a long-term follow-up.
Bar-Am A; Gamzu R; Levin I; Fainaru O; Niv J; Almog B
Gynecol Oncol; 2003 Oct; 91(1):149-53. PubMed ID: 14529675
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus mRNA and DNA testing in women with atypical squamous cells of undetermined significance: A prospective cohort study.
Thomsen LT; Dehlendorff C; Junge J; Waldstrøm M; Schledermann D; Frederiksen K; Kjaer SK
Int J Cancer; 2016 Oct; 139(8):1839-50. PubMed ID: 27004595
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
[No Abstract] [Full Text] [Related]
20. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.
Benevolo M; Vocaturo A; Caraceni D; French D; Rosini S; Zappacosta R; Terrenato I; Ciccocioppo L; Frega A; Giorgi Rossi P
J Clin Microbiol; 2011 Jul; 49(7):2643-50. PubMed ID: 21525231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
